A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever

Inclusion Criteria: 1. Aged 18 \~ 75 years (inclusive), no gender limitation. 2. Patients with neutrophilic deficiency after solid tumor chemotherapy, hematological tumor chemotherapy, hematopoietic stem cell transplantation, etc. (absolute neutrophil count (ANC) in peripheral blood \<500 /mm\^3 (0.5×10\^9 /L) for at least 72 hours at screening). 3. Persistent or recurrent fever (oral temperature ≥38℃ or axillary temperature ≥37.7℃ within 24 hours prior to randomization) after at least 72 hours on broad-spectrum antibiotics, and considering fever to be associated with suspected fungal infection. 4. Female patients must meet one of the following conditions: 1. Menopausal patients, menopause at least 1 year; 2. Patients of childbearing age: Negative for blood/urine pregnancy test before enrollment; agree to take a guaranteed, effective contraception during the study and within 4 weeks after the study. 5. Male patients and their partners must use effective contraception throughout the study period and up to 4 weeks after leaving the study. 6. Patients fully understand and voluntarily participate in this study and sign informed consent. Exclusion Criteria: 1. History of allergy to liposomes or amphotericin B. 2. Received systemic treatment of amphotericin B or amphotericin B-containing formulation within 10 days prior to enrollment. 3. Liposome used within 1 month before the signing informed consent. 4. Confirmed or clinically diagnosed invasive fungal infection or known uncontrolled bacteremia or sepsis at screening. 5. Eastern Cooperative Oncology Group (ECOG) performance status ≥3; 6. Abnormal liver function, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≥5 × the upper limit of normal (ULN), or ALT/AST ≥3 × ULN with total bilirubin ≥1.5 × ULN, or total bilirubin ≥3 × ULN. 7. Serum creatinine \> 2 × ULN. 8. Serum potassium concentration ≤3.0 mmol/L prior to the first administration, or serum potassium concentration ≤the lower limit of normal value (LLN) in patients undergoing digitalization. 9. 12-lead ECG presenting II or III degree atrioventricular block, long QT syndrome or corrected QT interval\>480 ms in the absence of a pacemaker. 10. Cardiac function grade III/IV (NYHA). 11. Tachyarrhythmia requiring intervention and a history of high-risk coronary heart disease such as unstable angina and acute coronary syndrome. 12. Human immunodeficiency virus (HIV) antibody or treponema pallidum specific antibody (TPHA) positive; active tuberculosis on CT of chest (to be determined by investigator). 13. Pregnant or lactating female. 14. A history of drug abuse (non-medical use of narcotic drugs or psychotropic substances) or drug dependence (narcotics, stimulants and psychotropic substances, etc.) within 2 years. 15. Plan to use prohibited drugs during the study period. 16. Enrolled in any other clinical trials of drugs or medical devices within 3 months prior to screening. 17. Life expectancy \< 2 months; 18. Not suitable for this study as decided by the investigator due to other reasons